AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26832658 — intervention group
Group type: COMPARATOR
Intervention: Macular laser photocoagulation in patients without prior anti-VEGF treatment
Number of subjects: 865
Study 23897775 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week for 10 weeks
Number of subjects: 70
Study 23897775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 23897775 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 70
Study 22293719 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine (basal 12 ml/h; bolus 4 ml)
Number of subjects: 36
Study 22293719 — intervention group
Group type: COMPARATOR
Intervention: 0.4% ropivacaine (basal 3 ml/h; bolus 1 ml)
Number of subjects: 36
Study 22293719 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine
Number of subjects: 36
Study 22293719 — intervention group
Group type: COMPARATOR
Intervention: 0.4% ropivacaine
Number of subjects: 36
Study 20598077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin low-molecular-weight heparin (LMWH) 5000 anti-Xa units, subcutaneously once daily for 6 months.
Number of subjects: 186
Study 20598077 — intervention group
Group type: COMPARATOR
Intervention: Placebo, subcutaneously once daily for 6 months.
Number of subjects: 186
Study 20598077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin low-molecular-weight heparin (LMWH) 5000 anti-Xa units.
Number of subjects: 186
Study 20598077 — intervention group
Group type: COMPARATOR
Intervention: Placebo.
Number of subjects: 186
Study 17637403 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge enoxaparin (40 mg once daily for 20 days)
Number of subjects: 140
Study 17637403 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily for 20 days)
Number of subjects: 140
Study 17637403 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge enoxaparin (40 mg once daily)
Number of subjects: 140
Study 17637403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 15310644 — intervention group
Group type: COMPARATOR
Intervention: NOBLOCK group (no neuromuscular blocking agent)
Number of subjects: 130
Study 15310644 — intervention group
Group type: EXPERIMENTAL
Intervention: BLOCK group (cisatracurium prior to LMA insertion)
Number of subjects: 130
Study 15310644 — intervention group
Group type: COMPARATOR
Intervention: NOBLOCK group
Number of subjects: 130
Study 15310644 — intervention group
Group type: EXPERIMENTAL
Intervention: BLOCK group
Number of subjects: 130
Study 15310644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 130
Study 12374899 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg)
Number of subjects: 8
Study 12374899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9661545 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive epidural bupivacaine (0.66 mL/kg 0.25%) with morphine (0.02 mg/kg) administered caudally before surgery
Number of subjects: 60
Study 9661545 — intervention group
Group type: COMPARATOR
Intervention: Postincisional administration of the same bupivacaine-morphine mixture after surgery
Number of subjects: 60
Study 9661545 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive epidural bupivacaine with morphine
Number of subjects: 60
Study 9661545 — intervention group
Group type: COMPARATOR
Intervention: Postincisional administration of the same bupivacaine-morphine mixture
Number of subjects: 60
Study 7714226 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone 100 mg twice daily
Number of subjects: 24
Study 7714226 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone 200 mg twice daily
Number of subjects: 24
Study 7714226 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 50 mg twice daily
Number of subjects: 24
Study 7714226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2757895 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-interferon (Roferon-A) administered as an intra-muscular injection (3 x 10(6) iu) once-a-day over 3 days
Number of subjects: 0
Study 2757895 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-interferon (Roferon-A)
Number of subjects: 0
Study 54852 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin infusion
Number of subjects: 7
Study 54852 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 60 infusion
Number of subjects: 7
Study 31253112 — intervention group
Group type: EXPERIMENTAL
Intervention: HealtheSteps™ program
Number of subjects: 118
Study 31253112 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 118
Study 27894985 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment for tuberculosis
Number of subjects: 7980
Study 27894985 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 7980
Study 27894985 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 25-34 years
Number of subjects: 7980
Study 27894985 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 35-44 years
Number of subjects: 7980
Study 27894985 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 45-54 years
Number of subjects: 7980
Study 27894985 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 55-64 years
Number of subjects: 7980
Study 27894985 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged >64 years
Number of subjects: 7980
Study 27894985 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-infected cases receiving antiretroviral therapy (ART)
Number of subjects: 7980
Study 26423504 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX group (0.12% chlorhexidine gluconate)
Number of subjects: 50
Study 26423504 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oils (EO) group
Number of subjects: 50
Study 26423504 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride (CPC) group
Number of subjects: 50
Study 26423504 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri group (triclosan)
Number of subjects: 50
Study 26423504 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamamelis virginiana (HV) group
Number of subjects: 50
Study 22576643 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate mobilization of the elbow joint
Number of subjects: 180
Study 22576643 — intervention group
Group type: EXPERIMENTAL
Intervention: Active mobilization after 2 days of sling use
Number of subjects: 180
Study 22576643 — intervention group
Group type: COMPARATOR
Intervention: Immobilization in a cast for 7 days (Control)
Number of subjects: 180
Study 21426603 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 23
Study 21426603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 20054744 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 42
Study 20054744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 17224860 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone treatment
Number of subjects: 56
Study 17224860 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 56
Study 15370901 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 4
Study 15370901 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron
Number of subjects: 4
Study 15370901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 11686419 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose inhaled fluticasone propionate (FP) 44 microg, two puffs twice daily for 4 weeks
Number of subjects: 18
Study 11686419 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zafirlukast (ZK) 20 mg, twice daily for 4 weeks
Number of subjects: 18
Study 11686419 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PB)
Number of subjects: 18
Study 11301564 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 1,000 mg every 3 hours (six times a day)
Number of subjects: 24
Study 11301564 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 1,000 mg four times a day
Number of subjects: 24
Study 11301564 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 1,000 mg three times a day
Number of subjects: 24
Study 11301564 — intervention group
Group type: COMPARATOR
Intervention: Single 5-mg/kg intravenous infusion of ganciclovir
Number of subjects: 24
Study 11301564 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 6,000 mg/day
Number of subjects: 24
Study 11301564 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 3,000 mg/day and 4,000 mg/day
Number of subjects: 24
Study 11301564 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 4,000 mg/day and 6,000 mg/day
Number of subjects: 24
Study 11301564 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dosages of ganciclovir
Number of subjects: 24
Study 7943789 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms/kg
Number of subjects: 60
Study 7943789 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms/kg
Number of subjects: 60
Study 7943789 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 60
Study 3062257 — intervention group
Group type: EXPERIMENTAL
Intervention: OPA therapy (2 cycles) for stage I/IIA
Number of subjects: 103
Study 3062257 — intervention group
Group type: EXPERIMENTAL
Intervention: OPA therapy (2 cycles) and COMP therapy (2 cycles) for stage IIB/IIIA
Number of subjects: 103
Study 3062257 — intervention group
Group type: EXPERIMENTAL
Intervention: OPA therapy (2 cycles) and COMP therapy (4 cycles) for stage IIIB/IV
Number of subjects: 103
Study 3062257 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (dosage of 35, 30 or 25 Gy depending on chemotherapy extent)
Number of subjects: 103
Study 30237584 — intervention group
Group type: EXPERIMENTAL
Intervention: rs11749255 in MSX2
Number of subjects: 1779
Study 30237584 — intervention group
Group type: EXPERIMENTAL
Intervention: IFLTD1 rs6487504
Number of subjects: 1779
Study 30237584 — intervention group
Group type: EXPERIMENTAL
Intervention: PTPRD rs324498
Number of subjects: 1779
Study 30237584 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score for RHTN
Number of subjects: 1779
Study 28886018 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxford Elbow Score (OES)
Number of subjects: 100
Study 28886018 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick Disabilities of the Arm, Shoulder, and Hand (Quick‐DASH)
Number of subjects: 100
Study 28886018 — intervention group
Group type: COMPARATOR
Intervention: Mayo Elbow Performance Index, pain (VAS), Short Form‐36, EuroQol‐5D
Number of subjects: 100
Study 26147010 — intervention group
Group type: EXPERIMENTAL
Intervention: P2G12 (monoclonal antibody derived from transgenic tobacco)
Number of subjects: 0
Study 26147010 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 23453465 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position (Group L)
Number of subjects: 100
Study 23453465 — intervention group
Group type: COMPARATOR
Intervention: Sitting position (Group S)
Number of subjects: 100
Study 20034685 — intervention group
Group type: COMPARATOR
Intervention: Metformin 850 mg/d
Number of subjects: 35
Study 20034685 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg/d + Atorvastatin 10 mg
Number of subjects: 35
Study 19833593 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous TENS (CTENS) and pharmacologic analgesia
Number of subjects: 100
Study 19833593 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent TENS (ITENS) and pharmacologic analgesia
Number of subjects: 100
Study 19833593 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS (PTENS) and pharmacologic analgesia
Number of subjects: 100
Study 19833593 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic analgesia alone (control)
Number of subjects: 100
Study 16918659 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg x kg(‐1) of ketamine before surgery (Group II)
Number of subjects: 90
Study 16918659 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg x kg(‐1) of ketamine after surgery (Group III)
Number of subjects: 90
Study 16918659 — intervention group
Group type: COMPARATOR
Intervention: No ketamine (Group I)
Number of subjects: 90
Study 16918659 — intervention group
Group type: EXPERIMENTAL
Intervention: No unwanted side effects noted in any group
Number of subjects: 90
Study 15479482 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg I.V. every 2 weeks)
Number of subjects: 0
Study 15479482 — intervention group
Group type: COMPARATOR
Intervention: Placebo (I.V. every 2 weeks)
Number of subjects: 0
Study 10976977 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy (10% dextrose and 0.075% xylocaine in bacteriostatic water)
Number of subjects: 27
Study 10976977 — intervention group
Group type: COMPARATOR
Intervention: Control (0.075% xylocaine in bacteriostatic water)
Number of subjects: 27
Study 9302444 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 200 mg intramuscularly every 2 weeks for 3 months
Number of subjects: 40
Study 9302444 — intervention group
Group type: COMPARATOR
Intervention: Placebo intramuscularly every 2 weeks for 3 months
Number of subjects: 40
Study 9302444 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy
Number of subjects: 40
Study 9302444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8391304 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms kg−1) as a single prophylactic 5-min infusion
Number of subjects: 281
Study 8391304 — intervention group
Group type: COMPARATOR
Intervention: High-dose metoclopramide (loading dose of 3 mg kg−1 followed by maintenance dose of 4 mg kg−1 infused over 8 h) plus dexamethasone (12 mg as a 30-min infusion)
Number of subjects: 281
Study 8391304 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 281
Study 8391304 — intervention group
Group type: COMPARATOR
Intervention: High-dose metoclopramide plus dexamethasone
Number of subjects: 281
Study 3540229 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg three times daily
Number of subjects: 0
Study 3540229 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 160 mg twice daily
Number of subjects: 0
Study 3540229 — intervention group
Group type: COMPARATOR
Intervention: Pindolol 7.5 mg twice daily
Number of subjects: 0
Study 3540229 — intervention group
Group type: COMPARATOR
Intervention: Labetalol 200 mg twice daily
Number of subjects: 0
Study 30216749 — intervention group
Group type: EXPERIMENTAL
Intervention: Diploma students (GNM)
Number of subjects: 633
Study 30216749 — intervention group
Group type: COMPARATOR
Intervention: Bachelor students (B.Sc. nursing)
Number of subjects: 633
Study 27312945 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (intramuscular testosterone undecanoate)
Number of subjects: 101
Study 24954162 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (almond-based beverage enriched with DHA)
Number of subjects: 15
Study 24954162 — intervention group
Group type: COMPARATOR
Intervention: Placebo (almond-based beverage without DHA)
Number of subjects: 15
Study 24954162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DHA and placebo groups
Number of subjects: 15
Study 24954162 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 15
Study 24954162 — intervention group
Group type: EXPERIMENTAL
Intervention: Training season
Number of subjects: 15
Study 22456632 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year school-based physical activity intervention
Number of subjects: 321
Study 22456632 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 321
Study 20550650 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Care Model implemented by trained practice nurse
Number of subjects: 336
Study 19001963 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial embolization (TAE)
Number of subjects: 90
Study 19001963 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Number of subjects: 90
Study 19001963 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergent cricothyrotomy and tracheostomy
Number of subjects: 90
Study 19001963 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior or posterior packing
Number of subjects: 90
Study 19001963 — intervention group
Group type: EXPERIMENTAL
Intervention: Penetrating wounds management
Number of subjects: 90
Study 19001963 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt trauma management
Number of subjects: 90
Study 19001963 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 90
Study 15953008 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of asparaginase (ASP) and steroids during the postinduction intensification phase, with high-risk patients receiving thrice the steroid dose compared to standard-risk patients.
Number of subjects: 91
Study 15953008 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients (≥10 years) receiving the same treatment.
Number of subjects: 91
Study 15953008 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk (HR) treatment group receiving the same treatment.
Number of subjects: 91
Study 12748666 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN) treatment for a median duration of 5 months (1-18 months) until a median of 1 month prior to transplantation.
Number of subjects: 106
Study 12748666 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IFN treatment).
Number of subjects: 106
Study 12748666 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN) treatment.
Number of subjects: 106
Study 12810146 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 171
Study 12810146 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 171
Study 12810146 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 171
Study 9579718 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 150 mg bd
Number of subjects: 60
Study 9579718 — intervention group
Group type: COMPARATOR
Intervention: co-amoxiclav 625 mg tds
Number of subjects: 60
Study 9579718 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin
Number of subjects: 60
Study 9579718 — intervention group
Group type: COMPARATOR
Intervention: co-amoxiclav
Number of subjects: 60
Study 7644852 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil (400 mg in bolus)
Number of subjects: 16
Study 7644852 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (200 mg in bolus)
Number of subjects: 16
Study 7644852 — intervention group
Group type: COMPARATOR
Intervention: Sodium Nitroprusside (500 micrograms in bolus)
Number of subjects: 16
Study 2528004 — intervention group
Group type: EXPERIMENTAL
Intervention: TE‐031 (clarithromycin) at a daily dosage of 400 mg in 2 divided doses
Number of subjects: 302
Study 2528004 — intervention group
Group type: COMPARATOR
Intervention: JM (josamycin) at a daily dosage of 1,200 mg in 3 divided doses
Number of subjects: 302
Study 2528004 — intervention group
Group type: EXPERIMENTAL
Intervention: TE‐031 (clarithromycin)
Number of subjects: 302
Study 2528004 — intervention group
Group type: COMPARATOR
Intervention: JM (josamycin)
Number of subjects: 302
Study 766340 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily rifampicin plus ethambutol (ER7)
Number of subjects: 575
Study 766340 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly rifampicin plus ethambutol (ER2)
Number of subjects: 575
Study 766340 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly rifampicin plus ethambutol (ER1)
Number of subjects: 575
Study 766340 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily for 2 months and then once-weekly rifampicin plus ethambutol (ER7ER1)
Number of subjects: 575
Study 766340 — intervention group
Group type: COMPARATOR
Intervention: Standard retreatment regimen of daily ethionamide plus pyrazinamide plus cycloserine (EtZC)
Number of subjects: 575
Study 30659739 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic yoga (DY)
Number of subjects: 26
Study 30659739 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 26
Study 28427086 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling for HPV-testing (intervention group)
Number of subjects: 667
Study 28427086 — intervention group
Group type: COMPARATOR
Intervention: Liquid-based cytology performed by a health-care provider (control group)
Number of subjects: 667
Study 25605528 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized JCP extract for five months over the pollen season
Number of subjects: 29
Study 25605528 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 29
Study 25605528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 23490237 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 66
Study 23490237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 21816071 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g n‐3 LC‐PUFA/d
Number of subjects: 60
Study 21816071 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2 g γ‐linolenic acid/d
Number of subjects: 60
Study 21816071 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 g n‐3 LC‐PUFA + 1.8 g γ‐linolenic acid/d
Number of subjects: 60
Study 21816071 — intervention group
Group type: COMPARATOR
Intervention: 3.0 g olive oil
Number of subjects: 60
Study 19143687 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained anaesthetic technician
Number of subjects: 10
Study 19143687 — intervention group
Group type: COMPARATOR
Intervention: Theatre nurse without training
Number of subjects: 10
Study 18473961 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose cytarabine with or without etoposide or mitoxantrone
Number of subjects: 0
Study 18473961 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed sequential chemotherapy regimens
Number of subjects: 0
Study 18473961 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth factors to increase leukaemia cell sensitivity
Number of subjects: 0
Study 15267080 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (21-mg transdermal patch)
Number of subjects: 12